Compare EEFT & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEFT | ADMA |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 1996 | 2012 |
| Metric | EEFT | ADMA |
|---|---|---|
| Price | $74.73 | $16.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $96.00 | $28.50 |
| AVG Volume (30 Days) | 798.4K | ★ 2.6M |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.05 | N/A |
| EPS | ★ 6.84 | 0.60 |
| Revenue | ★ $4,244,200,000.00 | $42,219,783.00 |
| Revenue This Year | $8.95 | $26.71 |
| Revenue Next Year | $6.29 | $21.78 |
| P/E Ratio | ★ $10.57 | $27.30 |
| Revenue Growth | 6.38 | ★ 43.85 |
| 52 Week Low | $64.34 | $13.76 |
| 52 Week High | $114.25 | $25.67 |
| Indicator | EEFT | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 50.52 |
| Support Level | $72.35 | $16.39 |
| Resistance Level | $76.17 | $17.90 |
| Average True Range (ATR) | 2.75 | 0.82 |
| MACD | 0.47 | 0.12 |
| Stochastic Oscillator | 93.44 | 72.99 |
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. It offers payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company's product offerings include comprehensive ATM, POS, card outsourcing, card issuing and merchant acquiring services, software solutions, money transfer services, etc. Its reportable operating segments are EFT Processing, epay, and Money Transfer. Maximum revenue is derived from its Money Transfer segment, which provides money transfer services across the world under the brand names Ria, AFEX, IME, and xe. Geographically, the company generates maximum revenue from the United States, followed by Germany, India, France, Greece, and other regions.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.